These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35263757)

  • 1. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
    Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
    Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Resiquimod (R848) has more stronger immune adjuvantivity than other tested TLR agonists].
    Shen Y; Zeng M; Qiu F; Tang H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):591-596. PubMed ID: 28502294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
    Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
    Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variable requirement of dendritic cells for recruitment of NK and T cells to different TLR agonists.
    Uchida T; Scumpia PO; Murasko DM; Seki S; Woulfe S; Clare-Salzler MJ; Moldawer LL
    J Immunol; 2007 Mar; 178(6):3886-92. PubMed ID: 17339488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
    Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
    Pufnock JS; Cigal M; Rolczynski LS; Andersen-Nissen E; Wolfl M; McElrath MJ; Greenberg PD
    Blood; 2011 Jun; 117(24):6542-51. PubMed ID: 21493800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
    Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
    J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic background influences the cellular and humoral immune responses to vaccines.
    Zeng M; Nourishirazi E; Guinet E; Nouri-Shirazi M
    Clin Exp Immunol; 2016 Nov; 186(2):190-204. PubMed ID: 27393001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.
    Kamath AT; Sheasby CE; Tough DF
    J Immunol; 2005 Jan; 174(2):767-76. PubMed ID: 15634897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.
    Hackstein H; Hagel N; Knoche A; Kranz S; Lohmeyer J; von Wulffen W; Kershaw O; Gruber AD; Bein G; Baal N
    PLoS One; 2012; 7(8):e43320. PubMed ID: 22927956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
    Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
    J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.
    Kastenmüller K; Wille-Reece U; Lindsay RW; Trager LR; Darrah PA; Flynn BJ; Becker MR; Udey MC; Clausen BE; Igyarto BZ; Kaplan DH; Kastenmüller W; Germain RN; Seder RA
    J Clin Invest; 2011 May; 121(5):1782-96. PubMed ID: 21540549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
    Sawaki J; Tsutsui H; Hayashi N; Yasuda K; Akira S; Tanizawa T; Nakanishi K
    Int Immunol; 2007 Mar; 19(3):311-20. PubMed ID: 17289654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
    Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
    Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.
    Xu S; Koldovsky U; Xu M; Wang D; Fitzpatrick E; Son G; Koski G; Czerniecki BJ
    Surgery; 2006 Aug; 140(2):170-8. PubMed ID: 16904966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.